HD204 vs IBI305

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

HD204

Developed by Intas Pharmaceuticals and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT03390686 · Phase 3 · active, not recruiting

This was a randomised, double-blind, active-controlled Phase 3 equivalence trial (625 patients randomised, per the sponsor) comparing HD204 with reference bevacizumab (Avastin), each with chemotherapy, in advanced non-squamous NSCLC. The primary endpoint was objective response rate at week 18, and the prespecified equivalence margin test succeeded (risk ratio 1.047, 95% CI 0.86 to 1.27), showing clinical equivalence with the reference product.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. The sponsor's topline release reports 625 patients randomised 1:1; the registry lists 650 enrolled.

Reported efficacy

Overall Response Rate (ORR) at Week 18 (18 weeks from randomization): SAMSON-II (NCT03390686), primary endpoint ORR at week 18: HD204 48.7% vs reference bevacizumab 46.5%; risk ratio 1.047 (95% CI 0.86-1.27), within prespecified equivalence margin (met)

Result source: NCT03390686

IBI305

Marketed by Innovent Biologics

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT02954172 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial with 450 enrolled participants (220 and 221 in the reported primary analysis groups). Its primary clinical endpoint, objective response rate at 18 weeks, met the prespecified equivalence criterion: 44.3% with IBI305 versus 46.4% with bevacizumab, with the 90% confidence interval for the odds ratio entirely within the 0.75–1.33 equivalence margin.

Reported efficacy

Objective Response Rate (18 weeks): Objective response rate at 18 weeks: 44.3% IBI305 (n=221) vs 46.4% bevacizumab (n=220); odds ratio 0.90 (90% CI 0.756–1.077), prespecified equivalence margin 0.75–1.33. (met)

Result source: NCT02954172

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHD204IBI305
PFS, median—Trial running · NCT033906868.4 vs 8.3vs Bevacizumabn 221NCT02954172
OS, median—Trial running · NCT0339068618.0n 221NCT02954172
ORR—Trial running · NCT0339068644.3% vs 46.4%vs Bevacizumabwk 18 · n 221NCT02954172
Duration of response, median—Trial running · NCT03390686—Not reported

PFS, median

HD204
—Trial running · NCT03390686
IBI305
8.4 vs 8.3vs Bevacizumabn 221NCT02954172

OS, median

HD204
—Trial running · NCT03390686
IBI305
18.0n 221NCT02954172

ORR

HD204
—Trial running · NCT03390686
IBI305
44.3% vs 46.4%vs Bevacizumabwk 18 · n 221NCT02954172

Duration of response, median

HD204
—Trial running · NCT03390686
IBI305
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

HD204
SAMSON-II (NCT03390686), primary endpoint ORR at week 18: HD204 48.7% vs reference bevacizumab 46.5%; risk ratio 1.047 (95% CI 0.86-1.27), within prespecified equivalence margin NCT03390686 · Phase 3 · design grade: strong · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. HD204: 0 of 4 rows · IBI305: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIBI305
Dropout rate
1.3%a
NCT02954172 · Phase 3 · combination
Discontinued due to AEs
—a
NCT02954172 · Phase 3 · combination
Serious AEs
33.5%a
NCT02954172 · Phase 3 · combination
Most frequent reported AEs
a
white blood cell count decreased 71.9%
neutrophil count decreased 70.5%
platelet count decreased 50.4%
NCT02954172 · Phase 3 · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

IBI305

ORR 44.3% (n=221) vs 46.4% (n=220) Bevacizumab @ 18wk
responder rate · % of participants
NCT02954172 · Phase 3 · combination
Overall Survival 18.02 vs NA Bevacizumab months
time to event · months
NCT02954172 · Phase 3 · combination
PFS 8.43 vs 8.26 Bevacizumab months
time to event · months
NCT02954172 · Phase 3 · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HD204's landscape · IBI305's landscape